Kanada IPO: MariCann Inc.

Danbel Ventures Inc. gibt bekannt, dass sie ein "binding letter agreement" mit MariCann Inc. eingegangen sind, das vorsieht, 100% des ausstehenden Kapitals von MariCann zu erwerben (Reverse Takeover von Danbel durch Maricanns Aktionäre). Im Rahmen der Transaktion wird Danbel die Zustimmung der Aktionäre für Folgendes beantragen: (i) die Transaktion an sich, (ii) Namensänderung in MariCann, (iii) eine Konsolidierung der Stammaktien im Verhältnis von 1:X, X= such number of Danbel shares that results in Danbel having a maximum of 1,250,000 post-Consolidation common shares at a deemed price of $1.00 per share outstanding on a fully diluted basis on the closing date)  (Iv) die Wahl von fünf neuen Vorstandsmitgliedern zur Ablösung des aktuellen Vorstandes. Darüber hinaus werden alle ausstehenden Schulden von Danbel durch die Ausgabe von 5,5 Mio. Stammaktien abgewickelt und alle nicht ausgeübten Mitarbeiteraktienoptionen von Danbel unmittelbar vor dem Abschluss der Transaktion annulliert.

Gemäß den Bedingungen der Transaktion wird jede ausgegebene und ausstehende Stammaktie von MariCann gegen eine Stammaktie der neuen Firma getauscht. Darüber hinaus werden alle ausstehenden Mitarbeiteraktienoptionen und Kaufoptionen von MariCann gegen gleichwertige Optionen oder einen Optionsscheinsscheine der neuen Firma getauscht.

MariCann completed a $22,500,000 financing on the date hereof (the "Financing") with Dundee Securities Ltd. (the "Agent"). Pursuant to the terms of the Financing, MariCann issued 22,500 units (the "Units"), with each Unit comprised of one senior unsecured convertible debenture with a principal amount of $1,000 (a "Debenture") and 500 common share purchase warrants (the "Warrants"). Immediately prior to completion of the Transaction, the principal amount of the Debentures will be converted into common shares of MariCann at a conversion price of $1.00 per share and subsequently be exchanged for common shares of the Resulting Issuer pursuant to the Transaction. The Warrants will similarly be exchanged pursuant to the Transaction or will otherwise be exercisable into common shares of the Resulting Issuer at an exercise price of $1.25 per share for a period of two years from the Listing Date, subject to an accelerated expiry in the event that the volume weighted average price of the Resulting Issuer common shares for any 20 consecutive trading days equals or exceed $1.90.

As partial consideration for their services, the Agent was issued 900,000 compensation options (the "Compensation
Options"). Each Compensation Option will be exchanged pursuant to the Transaction or will otherwise be exercisable to purchase one unit of the Resulting Issuer at an exercise price of $1.00 for a period of two years from the Listing Date. Each unit will be comprised of one common share and one common share purchase warrant of the Resulting Issuer, with each warrant entitling the holder to acquire one common share of the Resulting Issuer for a period of two years from the Listing Date.

Upon completion of the Transaction, it is anticipated that the Resulting Issuer will have approximately 68,701,298 Resulting Issuer common shares issued and outstanding, which includes the conversion of the Debentures issued under
the Financing. It is also anticipated that there will be 16,536,355 warrants and stock options of the Resulting Issuer outstanding, exercisable into 16,536,355 Resulting Issuer common shares and 900,000 Compensation Options
outstanding.

About MariCann

MariCann is a vertically integrated producer and distributor of marijuana for medical purposes. The company was founded in 2013 and is based in Langton, Ontario where it operates a cultivation, marijuana extraction and distribution business under federal licence from the Government of Canada. As one of 36 companies with a federal licence to cultivate cannabis and one of 22 independent licensed producers with a federal licence to process and distribute cannabis, MariCann services a patient base with more than 3,000 active patients. MariCann is currently undertaking an expansion of the cultivation and support facilities to support existing and future patient growth.

Originalmeldung